Jan-Philip Meyer

Title: Jan-Philip Meyer: Innovator in Radioligand Development

Introduction

Jan-Philip Meyer is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of medical imaging, particularly in the development of radioligands for pretargeted PET imaging. His innovative work aims to enhance cancer detection and treatment methodologies.

Latest Patents

Jan-Philip Meyer holds a patent titled "Radioligands for pretargeted PET imaging and methods of their therapeutic use." This patent describes Tz/TCO-based pretargeting strategies utilizing an Al[F]-NOTA-labeled tetrazine radioligand. This imaging strategy allows for the delineation of cancer at earlier time points compared to other imaging techniques. Additionally, it reduces the radiation dose to healthy tissues when compared to directly labeled antibodies. The Al-based fluorine imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because it has a shorter half-life and is more readily available for integration into hospital workflows.

Career Highlights

Jan-Philip Meyer is affiliated with the Memorial Sloan Kettering Cancer Center, where he continues to advance his research in medical imaging. His work is pivotal in improving cancer diagnostics and treatment options.

Collaborations

Some of his notable coworkers include Brian Zeglis and Jason S. Lewis, who contribute to the collaborative efforts in his research endeavors.

Conclusion

Jan-Philip Meyer is a key figure in the field of radioligand development, with a focus on enhancing cancer imaging techniques. His innovative patent work and collaborations are paving the way for advancements in medical diagnostics.